Summary

The North America infusion devices market size is projected to reach US$ 9,116.47 million by 2031 from US$ 5,494.15 million in 2023. The market is expected to register a CAGR of 6.5% during 2023–2031.

According to the US Census Bureau, the number of Americans aged 65 and above is expected to rise from 58 million in 2022 to 82 million by 2050, which is a 47% increase. Additionally, the share of the total population for the 65-and-older age group is projected to rise from 17% to 23%. According to Statistics Canada, in 2022, almost ~18.8% of Canadians were aged 65 years. Almost 20% of the Canadian population is aged 65 years and above. Furthermore, population projections suggest that 21% to 29% of Canadians could be aged 65 or above by 2068.

A few key benefits of infusion therapy administered in senior populations are listed below.

• Rehydration and electrolyte balance: Dehydration can be a higher risk for seniors due to factors such as decreased thirst, certain medications, and changes in kidney function. IV fluids can help seniors maintain the necessary hydration and electrolyte levels for overall health.

• Nutrition support and improvement: Aging makes it harder for human bodies to consume the right nutrients, increasing the risk of chronic illnesses. Infusion therapy provides a direct way for seniors to get essential minerals, vitamins, and amino acids efficiently.

• Immune function reinforcement: Immune systems of elderly people may need extra support, as they are more vulnerable to infections. Infusion therapy can deliver immune-boosting nutrients such as vitamin C, zinc, and glutathione directly to the body.

• Pain management: Many seniors deal with chronic pain daily, affecting their quality of life. Infusion therapy can quickly and effectively manage pain by delivering medication directly into the bloodstream, providing relief and reducing inflammation.

Thus, the increasing geriatric population drives the demand for infusion devices across North America.

Strategic Initiatives by Market Players

Various market players focus on strategic developments such as product launches, mergers, acquisitions, and collaborations to develop advanced products that help ease the treatment of chronic disorders such as diabetes, cancer, chronic pain among others. Following are a few recent developments in the North America infusion devices market.

• In April 2024, Mackenzie Health launched a technology in Canada that allows for two-way information flow between an intravenous (IV) medication pump and a patient’s electronic medical record. The technology, known as BD Alaris EMR Interoperability, eliminates the need for healthcare professionals to manually program pumps. It sends infusion safety information back to Epic EMR, reducing the risk of administration errors and providing an accurate infusion record in the EMR.

• In November 2022, Medtronic plc announced the launch of Medtronic Extended infusion set in the US. It is the first and only infusion set labeled for up to seven-day wear. An infusion set is tubing that delivers insulin from an insulin pump to the body and usually needs to be changed every two to three days.

• In May 2022, Fresenius Kabi acquired Ivenix and its advanced infusion pump technology, expanding its portfolio of advanced infusion pumps and solutions for healthcare professionals to address healthcare needs across the care continuum. Fresenius Kabi also announced that it has rapidly expanded its infusion therapy portfolio in the US, obtaining FDA approvals for multiple IV solutions in anticipation of qualifying its North Carolina manufacturing site to supply the US customers with IV solutions.

• In March 2022, Fresenius Kabi received 510(k) regulatory clearance from the FDA for its wireless Agilia Connect Infusion System. The system includes the Agilia Volumetric Pump and the Agilia Syringe Pump with Vigilant Software Suite-Vigilant Master Med technology. Both pumps are the first to be cleared following TIR101 standards, which were developed by the Association for the Advancement of Medical Instrumentation (AAMI) in 2021.

An upsurge in the number of product approvals, launches, and strategic collaborations is likely to create lucrative opportunities for the infusion devices market in the future.

End User-Based Insights

Based on end user, the North America infusion devices market is divided into hospitals and specialty clinics, homecare settings, ambulatory surgical centers, and others. The hospitals and specialty clinics segment dominated the market in 2023. The homecare settings segment is anticipated to register the highest CAGR during 2023–2031. Hospitals and clinics are primary contact points for patients to get their diagnosis done and opt for treatment options and alternatives. Available infrastructure in hospitals and clinics can provide high-quality care for patients suffering from any disease condition as they have access to advanced medical devices. The hospitals and clinics segment is projected to hold a considerable market share as a majority of patients in emerging nations and developed countries prefer visiting hospitals for health-related problems.

Infusion pumps are being used on a large scale in hospitals and clinics, owing to the additional benefits offered by the pumps such as precision, accuracy, and ease of use. The pumps can be used for applications such as chemotherapy, pain management, and diabetes management, which are the major reasons for patients being admitted for longer and shorter duration.

WellSpan Health and CareFusion, a BD company, jointly announced the implementation of the Alaris System across all four WellSpan hospitals. WellSpan York Hospital is the first hospital to go live with new infusion devices and bi-directional interoperability between the electronic health record and infusion device.

Hence, the benefits and the multiple applications of infusion pumps fuel the North America infusion devices market growth for the hospitals and clinics segment.

By application, the market is segmented into diabetes, oncology, pain management, hematology, pediatrics, gastroenterology, and others. The diabetes segment held the largest share of the market in 2023, and it is projected to register the highest CAGR in the market during 2023–2031.

Based on end user, the North America infusion devices market is divided into hospitals and specialty clinics, homecare settings, ambulatory surgical centers, and others. The hospitals and specialty clinics segment dominated the market in 2023. The homecare settings segment is anticipated to register the highest CAGR during 2023–2031.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS

1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macro-economic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country level data:
4. North America Infusion Devices Market Landscape
4.1 Overview
4.2 PEST Analysis
4.3 Overview of Mainstream System for infusion Pumps by US
4.3.1 Syringe Infusion Pumps:
4.3.2 Volumetric Infusion Pumps:
4.4 List of Best-Selling infusion Pumps along with the Model Number
5. North America Infusion Devices Market – Key Market Dynamics
5.1 North America Infusion Devices Market – Key Market Dynamics
5.2 Market Drivers
5.2.1 Increasing Prevalence of Cancer
5.2.2 Growing Geriatric Population
5.3 Market Restraints
5.3.1 Frequent Product Recalls of Infusion Devices
5.4 Market Opportunities
5.4.1 Strategic Initiatives by Market Players
5.5 Future Trends
5.5.1 Growing Technological Advancements
5.6 Impact of Drivers and Restraints:
6. North America Infusion Devices Market Analysis
6.1 North America Infusion Devices Market Revenue (US$ Million), 2021–2031
6.2 North America Infusion Devices Market Forecast and Analysis
7. North America Infusion Devices Market Analysis – by Product Type
7.1 Infusion Pumps
7.1.1 Overview
7.1.2 Infusion Pumps: North America Infusion Devices Market – Revenue and Forecast to 2031 (US$ Million)
7.2 Infusion Sets
7.2.1 Overview
7.2.2 Infusion Sets: North America Infusion Devices Market – Revenue and Forecast to 2031 (US$ Million)
8. North America Infusion Devices Market Analysis – by Application
8.1 Diabetes
8.1.1 Overview
8.1.2 Diabetes: North America Infusion Devices Market – Revenue and Forecast to 2031 (US$ Million)
8.2 Oncology
8.2.1 Overview
8.2.2 Oncology: North America Infusion Devices Market – Revenue and Forecast to 2031 (US$ Million)
8.3 Pain Management
8.3.1 Overview
8.3.2 Pain Management: North America Infusion Devices Market – Revenue and Forecast to 2031 (US$ Million)
8.4 Hematology
8.4.1 Overview
8.4.2 Hematology: North America Infusion Devices Market – Revenue and Forecast to 2031 (US$ Million)
8.5 Pediatrics
8.5.1 Overview
8.5.2 Pediatrics: North America Infusion Devices Market – Revenue and Forecast to 2031 (US$ Million)
8.6 Gastroenterology
8.6.1 Overview
8.6.2 Gastroenterology: North America Infusion Devices Market – Revenue and Forecast to 2031 (US$ Million)
8.7 Others
8.7.1 Overview
8.7.2 Others: North America Infusion Devices Market – Revenue and Forecast to 2031 (US$ Million)
9. North America Infusion Devices Market Analysis – by End User
9.1 Hospitals and Specialty Clinics
9.1.1 Overview
9.1.2 Hospitals and Specialty Clinics: North America Infusion Devices Market – Revenue and Forecast to 2031 (US$ Million)
9.2 Homecare Settings
9.2.1 Overview
9.2.2 Homecare Settings: North America Infusion Devices Market – Revenue and Forecast to 2031 (US$ Million)
9.3 Ambulatory Surgical Centers
9.3.1 Overview
9.3.2 Ambulatory Surgical Centers: North America Infusion Devices Market – Revenue and Forecast to 2031 (US$ Million)
9.4 Others
9.4.1 Overview
9.4.2 Others: North America Infusion Devices Market – Revenue and Forecast to 2031 (US$ Million)
10. North America Infusion Devices Market – Country Analysis
10.1 North America
10.1.1 North America Infusion Devices Market Breakdown by Countries
10.1.2 North America Infusion Devices Market Revenue and Forecast and Analysis – by Country
10.1.2.1 North America Infusion Devices Market Revenue and Forecast and Analysis – by Country
10.1.2.2 United States: North America Infusion Devices Market – Revenue and Forecast to 2031 (US$ Million)
10.1.2.2.1 United States: North America Infusion Devices Market Breakdown by Product Type
10.1.2.2.2 United States: North America Infusion Devices Market Breakdown by Infusion Pumps
10.1.2.2.3 United States: North America Infusion Devices Market Breakdown by Infusion Sets
10.1.2.2.4 United States: North America Infusion Devices Market Breakdown by Application
10.1.2.2.5 United States: North America Infusion Devices Market Breakdown by End User
10.1.2.3 Canada: North America Infusion Devices Market – Revenue and Forecast to 2031 (US$ Million)
10.1.2.3.1 Canada: North America Infusion Devices Market Breakdown by Product Type
10.1.2.3.2 Canada: North America Infusion Devices Market Breakdown by Infusion Pumps
10.1.2.3.3 Canada: North America Infusion Devices Market Breakdown by Infusion Sets
10.1.2.3.4 Canada: North America Infusion Devices Market Breakdown by Application
10.1.2.3.5 Canada: North America Infusion Devices Market Breakdown by End User
10.1.2.4 Mexico: North America Infusion Devices Market – Revenue and Forecast to 2031 (US$ Million)
10.1.2.4.1 Mexico: North America Infusion Devices Market Breakdown by Product Type
10.1.2.4.2 Mexico: North America Infusion Devices Market Breakdown by Infusion Pumps
10.1.2.4.3 Mexico: North America Infusion Devices Market Breakdown by Infusion Sets
10.1.2.4.4 Mexico: North America Infusion Devices Market Breakdown by Application
10.1.2.4.5 Mexico: North America Infusion Devices Market Breakdown by End User
11. North America Infusion Devices Market – Industry Landscape
11.1 Overview
11.2 Growth Strategies in North America Infusion Devices Market
11.3 Organic Growth Strategies
11.3.1 Overview
11.4 Inorganic Growth Strategies
11.4.1 Overview
11.5 Company Positioning:
12. Company Profiles
12.1 Becton Dickinson and Co
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Fresenius Kabi AG
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 B Braun SE
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 CODAN US Corp
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Baxter International Inc
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Elimedical Inc
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 ICU Medical Inc
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 BPL Medical Technologies Pvt Ltd
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Nipro Corp
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 KD Scientific Inc
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments
12.11 Medtronic Plc
12.11.1 Key Facts
12.11.2 Business Description
12.11.3 Products and Services
12.11.4 Financial Overview
12.11.5 SWOT Analysis
12.11.6 Key Developments
12.12 Zimed Healthcare Ltd
12.12.1 Key Facts
12.12.2 Business Description
12.12.3 Products and Services
12.12.4 Financial Overview
12.12.5 SWOT Analysis
12.12.6 Key Developments
12.13 Terumo Corp
12.13.1 Key Facts
12.13.2 Business Description
12.13.3 Products and Services
12.13.4 Financial Overview
12.13.5 SWOT Analysis
12.13.6 Key Developments
12.14 Eitan Medical Ltd
12.14.1 Key Facts
12.14.2 Business Description
12.14.3 Products and Services
12.14.4 Financial Overview
12.14.5 SWOT Analysis
12.14.6 Key Developments
12.15 Polymedicure
12.15.1 Key Facts
12.15.2 Business Description
12.15.3 Products and Services
12.15.4 Financial Overview
12.15.5 SWOT Analysis
12.15.6 Key Developments
12.16 Moog Inc
12.16.1 Key Facts
12.16.2 Business Description
12.16.3 Products and Services
12.16.4 Financial Overview
12.16.5 SWOT Analysis
12.16.6 Key Developments
13. Appendix
13.1 About The Insight Partners
13.2 Glossary of Terms